Aurora Cannabis Inc (ACB)

Sep 28, 2026

Aurora Cannabis (NASDAQ:ACB) is gaining renewed attention due to strong momentum in international medical cannabis demand, which is boosting earnings estimates. The company has also been navigating an unsolicited takeover bid, which it urged shareholders to reject, emphasizing its independent strategy focused on regulated international medical markets. This dual focus on operational strength in medical cannabis and corporate defense highlights the company's efforts to differentiate itself and adapt within the evolving cannabis industry.

Sep 21, 2026

Aurora Cannabis Inc. (TSX:ACB) has provided an update focusing on its international medical cannabis expansion and its response to Curaleaf's pending offer. This development keeps Aurora Cannabis relevant in the Canadian cannabis sector, with the article emphasizing that the company's ability to convert this announcement into operational progress will be key. The ongoing narrative for Aurora and its peers will depend on consistent execution, timely updates, and how these align with broader sector trends.

Sep 16, 2026

Aurora Cannabis has rejected Curaleaf's latest application to halt its at-the-market (ATM) program, calling it a "desperate" attempt to divert attention from an inadequate hostile bid. Aurora asserts that Curaleaf's bid undervalues the company's assets and future potential, especially given Curaleaf's significant debt compared to Aurora's debt-free position. The company's board unanimously recommends shareholders reject Curaleaf's offer, emphasizing that the ATM program was established for long-term growth, not as a response to the hostile takeover.

Sep 15, 2026

Curaleaf Holdings is actively urging Aurora Cannabis shareholders to accept its takeover offer after Aurora's board declined the proposal. The offer values Aurora shares at $4.00, representing a 45% premium, and Curaleaf projects significant annual synergies and combined revenue of over $1.5 billion. Curaleaf highlighted Aurora's recent financial underperformance to support its case for the acquisition, with a tender offer deadline set for December 1, 2026.